Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia

High-density lipoproteins (HDL) can bind and neutralize lipopolysaccharides (LPS) in vitro and in vivo. HDL can also affect fibrinolytic activity and can directly influence platelet function by reducing platelet aggregation. In this study, the effects of reconstituted HDL (rHDL) on LPS-induced coagu...

Full description

Saved in:
Bibliographic Details
Published inThrombosis and haemostasis Vol. 77; no. 2; p. 303
Main Authors Pajkrt, D, Lerch, P G, van der Poll, T, Levi, M, Illi, M, Doran, J E, Arnet, B, van den Ende, A, ten Cate, J W, van Deventer, S J
Format Journal Article
LanguageEnglish
Published Germany 1997
Subjects
Online AccessGet more information

Cover

Loading…
Abstract High-density lipoproteins (HDL) can bind and neutralize lipopolysaccharides (LPS) in vitro and in vivo. HDL can also affect fibrinolytic activity and can directly influence platelet function by reducing platelet aggregation. In this study, the effects of reconstituted HDL (rHDL) on LPS-induced coagulation, fibrinolysis and platelet activation in humans were investigated. In a double-blind, randomized, placebo-controlled, cross-over study, eight healthy male volunteers were injected with LPS (4 ng/kg) on two occasions, once in conjunction with rHDL (40 mg/kg, given as a 4 h infusion starting 3.5 h prior to LPS injection), and once in conjunction with placebo. rHDL significantly reduced LPS-induced activation of coagulation (plasma levels of prothrombin fragment F1 + 2) and fibrinolysis (plasma levels of tissue type plasminogen activator antigen, t-PA). No effect was observed on LPS-induced inhibition of the fibrinolytic pathway (PAI-1) or on the transient thrombocytopenia elicited by LPS. Furthermore, rHDL treatment significantly enhanced the inhibition of collagen-stimulated inhibition of platelet aggregation during endotoxemia, but had no such effect on arachidonate-stimulated platelet aggregation. rHDL treatment per se also reduced collagen-induced platelet aggregation. These results indicate that rHDL modifies the procoagulant state associated with endotoxemia.
AbstractList High-density lipoproteins (HDL) can bind and neutralize lipopolysaccharides (LPS) in vitro and in vivo. HDL can also affect fibrinolytic activity and can directly influence platelet function by reducing platelet aggregation. In this study, the effects of reconstituted HDL (rHDL) on LPS-induced coagulation, fibrinolysis and platelet activation in humans were investigated. In a double-blind, randomized, placebo-controlled, cross-over study, eight healthy male volunteers were injected with LPS (4 ng/kg) on two occasions, once in conjunction with rHDL (40 mg/kg, given as a 4 h infusion starting 3.5 h prior to LPS injection), and once in conjunction with placebo. rHDL significantly reduced LPS-induced activation of coagulation (plasma levels of prothrombin fragment F1 + 2) and fibrinolysis (plasma levels of tissue type plasminogen activator antigen, t-PA). No effect was observed on LPS-induced inhibition of the fibrinolytic pathway (PAI-1) or on the transient thrombocytopenia elicited by LPS. Furthermore, rHDL treatment significantly enhanced the inhibition of collagen-stimulated inhibition of platelet aggregation during endotoxemia, but had no such effect on arachidonate-stimulated platelet aggregation. rHDL treatment per se also reduced collagen-induced platelet aggregation. These results indicate that rHDL modifies the procoagulant state associated with endotoxemia.
Author ten Cate, J W
Lerch, P G
Doran, J E
Pajkrt, D
van der Poll, T
van Deventer, S J
Illi, M
Arnet, B
van den Ende, A
Levi, M
Author_xml – sequence: 1
  givenname: D
  surname: Pajkrt
  fullname: Pajkrt, D
  organization: Laboratory of Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
– sequence: 2
  givenname: P G
  surname: Lerch
  fullname: Lerch, P G
– sequence: 3
  givenname: T
  surname: van der Poll
  fullname: van der Poll, T
– sequence: 4
  givenname: M
  surname: Levi
  fullname: Levi, M
– sequence: 5
  givenname: M
  surname: Illi
  fullname: Illi, M
– sequence: 6
  givenname: J E
  surname: Doran
  fullname: Doran, J E
– sequence: 7
  givenname: B
  surname: Arnet
  fullname: Arnet, B
– sequence: 8
  givenname: A
  surname: van den Ende
  fullname: van den Ende, A
– sequence: 9
  givenname: J W
  surname: ten Cate
  fullname: ten Cate, J W
– sequence: 10
  givenname: S J
  surname: van Deventer
  fullname: van Deventer, S J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/9157586$$D View this record in MEDLINE/PubMed
BookMark eNotkLtOwzAYhT0UlbawsiH5AQj4Eif2iMpVqsQCc-XL79YosaPYQfQdeGgq6HQ-6Xw6w1miWUwRELqi5JYSIe5yRQiXFW2EUELO0ILwmlQNq8U5Wub8SQhtaiXmaK6oaIVsFujnIXgPI8QSdIfhyLZknDwewaaYSyhTAYf3YbevHMQcygF3YUjDmAqEiFPENund1OkSUrzBPpgxxNQdcshYR4eHYwMdFKxtCV9_FnbT0dnh_dTriCG6VNI39EFfoDOvuwyXp1yhj6fH9_VLtXl7fl3fbyrLFSuVaJ1nUnmrDGe28YQyLbkRYLkA5piiymjGW2OaVigpBHhaA2cGjLSU1WyFrv93h8n04LbDGHo9HranV9gvPMNokw
CitedBy_id crossref_primary_10_3390_pharmaceutics15051504
crossref_primary_10_1161_01_RES_0000225982_01988_93
crossref_primary_10_1111_j_1348_0421_2010_00203_x
crossref_primary_10_1161_CIRCRESAHA_111_258673
crossref_primary_10_1161_01_ATV_0000094961_74697_54
crossref_primary_10_1097_01_shk_0000116778_27924_79
crossref_primary_10_1097_MD_0000000000031724
crossref_primary_10_1016_j_ejheart_2003_12_004
crossref_primary_10_1152_ajpregu_00285_2002
crossref_primary_10_1373_clinchem_2016_257725
crossref_primary_10_1097_00003246_200108000_00011
crossref_primary_10_1194_jlr_R037762
crossref_primary_10_1097_01_shk_0000191340_23907_a1
crossref_primary_10_1016_j_cjca_2012_05_003
crossref_primary_10_1073_pnas_97_4_1743
crossref_primary_10_1016_j_trsl_2006_08_002
crossref_primary_10_1016_S0021_9150_98_00247_0
crossref_primary_10_1186_s13054_020_02860_3
crossref_primary_10_1089_109629604773860291
crossref_primary_10_1007_s00134_006_0433_x
crossref_primary_10_1111_cts_12186
crossref_primary_10_1016_j_healun_2004_04_017
crossref_primary_10_1379_CSC_195R_1
crossref_primary_10_1016_S0022_2275_20_33363_0
crossref_primary_10_1345_aph_1C390
crossref_primary_10_1002_ejlt_200600015
crossref_primary_10_1007_s13346_010_0012_0
crossref_primary_10_5507_bp_2008_029
crossref_primary_10_1016_j_vph_2015_10_009
crossref_primary_10_1194_jlr_R039479
crossref_primary_10_1046_j_1537_2995_2001_41030382_x
crossref_primary_10_15406_jccr_2017_08_00305
crossref_primary_10_3390_jcm11040957
crossref_primary_10_1177_0968051907085986
crossref_primary_10_1586_14779072_6_9_1203
crossref_primary_10_3390_jcm9082606
crossref_primary_10_1097_MOL_0b013e32834701de
crossref_primary_10_1161_ATVBAHA_106_136325
crossref_primary_10_7793_jcoron_20_033
crossref_primary_10_1111_j_1348_0421_2009_00203_x
crossref_primary_10_1097_ALN_0000000000003155
crossref_primary_10_1053_spid_2001_19231
crossref_primary_10_1093_cvr_cvu137
crossref_primary_10_1016_j_ccc_2005_08_008
crossref_primary_10_1093_cvr_cvu139
crossref_primary_10_3390_ijms22115980
crossref_primary_10_1097_01_BCR_0000066812_96811_28
crossref_primary_10_1016_S0021_9150_01_00651_7
crossref_primary_10_1016_j_bbalip_2007_10_001
crossref_primary_10_3389_fonc_2014_00101
crossref_primary_10_1016_S0169_409X_01_00109_0
crossref_primary_10_1080_13547500601160536
crossref_primary_10_4161_viru_26514
crossref_primary_10_1172_JCI5006
crossref_primary_10_1016_j_ijpharm_2021_120272
crossref_primary_10_1160_TH17_03_0196
crossref_primary_10_1016_j_jacc_2008_03_016
crossref_primary_10_1097_01_shk_0000111661_09279_82
crossref_primary_10_1128_CMR_16_3_379_414_2003
crossref_primary_10_1126_sciadv_abd0130
crossref_primary_10_1097_MOL_0b013e328355ca25
crossref_primary_10_1161_ATVBAHA_118_310788
crossref_primary_10_1016_S0735_1097_99_00448_9
crossref_primary_10_1097_01_CCM_0000063260_07222_76
crossref_primary_10_1161_01_RES_0000124302_20396_B7
crossref_primary_10_3389_fendo_2023_1275132
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1055/s-0038-1655958
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 9157586
Genre Clinical Trial
Randomized Controlled Trial
Journal Article
GroupedDBID ---
.55
.GJ
0R~
0VX
123
1KJ
4.4
53G
5RE
AAQQT
ABJNI
ABOCM
ACGFO
ACGFS
AENEX
AFFNX
AHRSK
ALMA_UNASSIGNED_HOLDINGS
BR6
C45
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
H13
J5H
NPM
OVD
P2P
RTC
RTE
SJN
TEORI
UCJ
X7M
ZGI
ZXP
ID FETCH-LOGICAL-c392t-57df289fc9b32c6f012a83b5ec35e2d2919ba237bb6759855ef14e32beb8c1242
ISSN 0340-6245
IngestDate Sat Sep 28 07:38:56 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c392t-57df289fc9b32c6f012a83b5ec35e2d2919ba237bb6759855ef14e32beb8c1242
PMID 9157586
ParticipantIDs pubmed_primary_9157586
PublicationCentury 1900
PublicationDate 19970000
PublicationDateYYYYMMDD 1997-01-01
PublicationDate_xml – year: 1997
  text: 19970000
PublicationDecade 1990
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle Thrombosis and haemostasis
PublicationTitleAlternate Thromb Haemost
PublicationYear 1997
SSID ssj0016495
Score 1.8430259
Snippet High-density lipoproteins (HDL) can bind and neutralize lipopolysaccharides (LPS) in vitro and in vivo. HDL can also affect fibrinolytic activity and can...
SourceID pubmed
SourceType Index Database
StartPage 303
SubjectTerms Adult
Blood Coagulation - drug effects
Cross-Over Studies
Cytokines - blood
Double-Blind Method
Endotoxemia - blood
Endotoxemia - drug therapy
Endotoxins - adverse effects
Endotoxins - antagonists & inhibitors
Fibrinolysis - drug effects
Humans
Lipopolysaccharides - antagonists & inhibitors
Lipoproteins, HDL - pharmacology
Lipoproteins, HDL - therapeutic use
Male
Peptide Fragments - analysis
Plasminogen Activator Inhibitor 1 - analysis
Platelet Activation - drug effects
Platelet Aggregation
Prothrombin - analysis
Title Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia
URI https://www.ncbi.nlm.nih.gov/pubmed/9157586
Volume 77
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLamRaBeEFvFLh-4gaFx4izHikUVotUcplJvlbfQFE08ogGh_ob-CH4q79nOxC2LgEs0ikdW4vfp5a3fI-SZrJBHqbBMGylYUeua1XnZsoJLTPqJ2hrM6O4flHuHxfsjcTSbfU-qlr4M6qU-_2Vfyf9IFe6BXLFL9h8ku94UbsBvkC9cQcJw_SsZv4nTTQYMeyeVGd7LjUUA5jkyEjODheo4JaJbOc_N0PWYJ9BOfowDvPCwW2wA6F2gKfEUArAGH6bBc26E6O3Y2Rim-9ke3Fr3zS47mdq5i5PPbqncuM2JtEsHduhZtzbh5_L0U2gXWtccf7BxMNV8mviF7VVIdzF3IT-ymP78tZuiuSY28lVJ3CL2a2HjAQ9kkqMujiNdusQlDoo190wIPyv8HYHcGGcMM5wsK8E_CkzwifRXSy_-JgPLNNBu_3HxCv12XNkgG1WNGvQAo0ExS1UWfqrP-k1GUlAhXl1-oi1yPe5zxXvxVsziFrkZ3Q-6G7B0m8xsf4fc2I8FFnfJRQopGiFFXUsvQYqmkKIJpKjraQKpFzQFFAUk0BFQdAIUDYCiHlA0AdQ9cvju7eL1HosDO5gGM3tgojItOPCtblTOddmC8SPrXAmrc2G54U3WKMnzSilwU5taCNtmhc25sqrWYGjybbLZu97eJ1RzIythCq6VLZQRcqfibWaF4UZlMhMPyHY4x-NVYGU5jgf88HcLj8jWBMPH5FoLSsA-AYtyUE-9WH8AH5581w
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+effects+of+reconstituted+high-density+lipoprotein+on+coagulation%2C+fibrinolysis+and+platelet+activation+during+human+endotoxemia&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Pajkrt%2C+D&rft.au=Lerch%2C+P+G&rft.au=van+der+Poll%2C+T&rft.au=Levi%2C+M&rft.date=1997-01-01&rft.issn=0340-6245&rft.volume=77&rft.issue=2&rft.spage=303&rft_id=info:doi/10.1055%2Fs-0038-1655958&rft_id=info%3Apmid%2F9157586&rft_id=info%3Apmid%2F9157586&rft.externalDocID=9157586
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon